We are thrilled to share that we will be attending the Swiss Biotech Day 2026 in Basel from May 4–5. Our team is looking forward to connecting with the community and is excited to discuss your projects in Basel.

Through its participation in the Microphysiological Systems (MPS) initiative, abc biopply becomes part of a dynamic international network committed to fostering industry-wide collaboration. The initiative aims to accelerate the adoption and regulatory acceptance of next-generation technologies that refine, reduce, and ultimately replace the use of animals in research.

abc biopply is looking forward to connect with its clients again at the BioEurope Spring in Lisboa– discovering abc biopplys Organoid Services expertise together

By joining EUROoCS – the European OrganonChip Society, abc biopply becomes part of a vibrant, international community dedicated to advancing OrganonChip research, fostering collaboration, and driving scientific innovation across academia, industry, healthcare, and regulatory stakeholders.

Basel, Switzerland — February 5, 2026 — abc biopply announces today the opening of its new Organoid Competence Center at the Switzerland Innovation Park Basel Area. With this new location, the company expands its portfolio of highly standardized and fully integrated Organoid CRO services and brings them for the first time to Basel — one of the world’s leading hubs for drug discovery and development.

January 27, 2026, Basel, Switzerland & Newark — abc biopply ag and Pathways Preclinical Partners (“Path2P”) today announced a new collaboration aimed at enforcing the integration of abc biopply’s cutting-edge preclinical NAM technology 3D CoSeedis™ within global drug development networks in the US.

abc biopply has released a white paper demonstrating the unprecedented quality of 3D CoSeedis™ in the production of highly homogenous and uniform spheroids for the use in high-throughput and high-content screening applications. Together with Union Biometrica, Inc. (USA) the paper shows how 3D CoSeedis™ can be used as a manufacturing tool to produce large quantities of homogenous and uniform 3D spheroids in a HTS/HCS-compatible 384-well format. The 3D CoSeedis™ platform thereby not only sets new standards in high-volume production of 3D spheroids but it also helps to substantially increase screening efficiency. Download your copy of the paper here and contact us for further questions and information.

Join Dr. Arne-Christian Faisst, Founder & CEO of abc biopply ag, and Dr. Yuki Yamamoto, Co-founder & CEO of HiLung Inc., as they share insights into the latest advancements in Micro-Physiological Systems (MPS) and organoid research on the 26th November 2025 from 09:00-10:00 CET

We are thrilled to share that we are exhibiting with our strategic partner Preclina at this year's BioEurope in Vienna from Nov. 3-5. Come and visit us at Stand Number C192.

We are delighted to announce that Arne Faisst will be attending Bio Europe in Vienna from Nov. 3-5th 2025, a Global Biopharma Partnering Event. Meet us there!

We’re excited to share that Agne will be participating in Bio Europe 2025 in Vienna, taking place from November 3–5. This global biopharma partnering event is a great opportunity to connect. Meet us There!

SOLOTHURN, Switzerland & ILLKIRCH-GRAFFENSTADEN, France – [09/10/2025] – abc biopply ag, a Swiss biotech company specializing in humanized 3D disease models, and Inoviem Scientific, a French bioanalytical R&D company, have entered a strategic collaboration to develop and commercialize a new preclinical service for the pharmaceutical and biotech industries. This joint effort will create a highly predictive, patient-relevant drug testing platform by uniquely integrating Inoviem’s direct access to fresh patient tumor biopsies with abc biopply’s proprietary 3D multi-organoid technology™.

On October 8, 2025, ATON SA announced a key partnership between its subsidiary Inoviem Scientific and the Swiss company abc biopply. This partnership aims to develop new solutions in preclinical oncology. Inoviem Scientific, specialized in translational pharmacology, brings its unique access to fresh tumor biopsies and its “Pharmacology on the Spot” technology, preserving the integrity of the tumor microenvironment. For its part, abc biopply uses its 3D multi-organoid™ technology to create miniaturized organ models.

We're excited to share that Arne Faisst will be joining the Festival of Biologics in Basel, taking place from September 30th to October 2nd 2025. Meet us there!

We are pleased to announce that Agne Vaitkeviciene will be attending the Festival of Biologics in Basel from September 30th to October 2nd 2025. Meet us there!

We are delighted to announce that Agne Vaitkeviciene is attending this year's Life Science Baltics Event. Meet us there!

Zurich, Switzerland – August 8, 2025 – In a groundbreaking collaboration, abc biopply AG, the Zurich University of Applied Sciences (ZHAW), and the University of Zurich (UZH) have joined forces to develop a next-generation 3D multi-organoid in vitro platform designed to transform drug development and personalized cancer therapy. The initiative is supported by the Swiss national funding agency Innosuisse.

We are pleased to announce that Agne Vaitkeviciene will be present at the Biotechgate Digital Partnering Event on August 25-29th 2025.

We are thrilled to welcome Agne Vaitkeviciene as the newest member of our abc biopply team. Agne will be joining us as Director Business Development, bringing over 15 years of experience in the CRO market for drug discovery/development and preclinical project management. We are excited about the valuable contributions Agne will make and look forward to a successful collaboration.

As a Swiss life sciences company, a member of the Swiss Biotech Association and a leading preclinical CRO and organoid service innovator, we are delighted to once again be taking part in Swiss Biotech Day in Basel, one of the world's most important biotechnology conferences. The Swiss Biotech Day offers a valuable platform for knowledge exchange, innovation, and collaboration. We look forward to presenting our current initiatives, engaging in discussions about the future of biotech, and exploring new partnership opportunities. Visit us at the event and learn more about what drives our work. For more information about the Swiss Biotech Day, visit: swissbiotechday.ch

This week the FDA announced that it would phase out animal testing requirements for monoclonal antibodies and other drugs, citing the need for more effective, human-relevant screening methods. According to the Agency it will promote Human-Based Lab Models:

Back from BioEurope Spring 2025, the entire abc biopply team would like to take this opportunity to thank our customers, partners and friends in Milan for the exciting exchange and inspiring discussions. At the same time, a big thank you to our Korean friends from Preclina, with whom we were able to run the stand at the congress this year. We are already looking forward to meeting everyone again in Vienna in November.

Our experts will be onsite in Milan at BioEurope, booth #104 on level 0, alongside our partner CRO Preclina. We are eager to discuss your outsourcing needs and share insights on how we can support and accelerate your drug discovery programs. By introducing the cutting-edge technologies of abc biopply and Preclina as an integrated service package, we aim to enhance our offerings and provide even greater support for your research and drug development.

At abc biopply, we have already started preparing for this year's attendance at BioEurope Spring 2025 in Milan.We are happy to have our Research and Devepment Scientist Dr. Raquel Sousa joining us this year.

Solothurn, Switzerland and Seoul, Korea – abc biopply AG, a pioneer innovator of humanized multi-organoid disease models, and Preclina Inc., a preclinical contract research organization specializing in immune related disorders and humanized animal models, have announced a strategic collaboration. The partnership between the two companies will provide customers with end-to-end project planning on humanized preclinical models from early in vitro to in vivo studies and will revolutionize predictability in drug development.

We are proud to announce that abc biopply has officially been validated as a Biosafety Level 2 (BSL 2) Laboratory by the esteemed Waste Management and Operations Department of the Office for Waste, Water, Energy and Air of the Canton of Zurich on behalf of the Office for the Environment of the Canton of Zug.

Missed yesterday's webinar on "A New Tool in Regenerative Medicine: Employing 3D Cultures of Adipose Stromal Cells for Advanced Cartilage Repair "? Dive into the recording now for cutting-edge insights.

We are delighted to introduce Dr. Raquel Sousa as the newest addition to our abc biopply team. Dr. Sousa will be joining us as a Research and Development Scientist at our laboratory in Cham, starting on November 1st. Her expertise will strengthen our laboratory group, focusing on preclinical study projects and advancing our 3D assay portfolio. We are excitedly looking forward to the valuable contributions Dr. Sousa will make towards our organization's growth and success.

We are pleased to announce that abc biopply AG has joined the Swiss Biotech Association. As a member of the association, we are now part of a vibrant network of biotech professionals and companies in Switzerland.

The year 2023 is starting with positive news after the U.S. Congress passed the FDA Modernization Act 2.0, which removes the requirement for animal testing in drug development. The decision paves the way to finally allowing the use of data generated from new alternative methods (NAMs), such as abc biopply's 3D multi-organoid in chip assays.

We are pleased to welcome Dr. Olivera Evrova as a new member to our abc biopply team. Olivera will strengthen our laboratory group in the execution of preclinical study projects and the further development of our 3D assay portfolio.

abc biopply enjoyed a very successful participation at the Festival of Biologics 2022 in Basel, Switzerland. A big thank you to all our customers and potential partners for the enthusiastic feedback on our microphysiological preclinical disease models and assays. See you in San Diego.

Read the most recent article in DrugDiscovery online about abc biopply's activities.

20.08.2022 Seattle/Solothurn Seattle-based primary cell biology CRO ReachBio and Swiss biotech abc biopply announced today a partnership to jointly co-market their preclinical test models. The two companies plan to support their clients with an even more predictive assay portfolio to further increase the efficiency of their drug discovery and development services.

In collaboration with the American Physiological Society (APS) and our American partner nanoscaleLABS, abc biopply is organizing a webinar on the use of 3D CoSeedis™ in high throughput ex vivo propagation of multiple myeloma cells. Dr Johannes Waldschmidt and Dr Andreas Thomsen from the University of Freiburg in Germany together with Dr Marco Leu from abc biopply will discuss the importance of reliable 3D preclinical disease models in accurate and predictive compound testing.

Solothurn 08.02.2022 Swiss Biotech Company abc biopply reports revenues in 2021 more than doubled in its core business with its preclinical 3D tumor models. The company has started offering these specialized CRO services to its biotech and pharma clients since 2019.

abc biopply and SEED Bioscienses have recently started to co-develop an inovative new method to make 3D cell cultures assessible for HTS applications. In this collaboration, abc biopply provides highly homogenous and uniform 3D cultures in large quantities using its prorietary 3D CoSeedis™ platform whereas SEED Bioscienses uses its DISPENCELL technology to disperse them into HTS compatible multi-well plates. Finally, HTS users will gain access to a reliable source of high quality 3D cultures in sufficient quantities to reach unprecedented efficacy in HTS of 3D cultures.

We are very pleased to be one of the key players mentioned in the most recent 3D cell culture market report of IndustryARC.

Find the article about abc biopply on the startupticker.ch platform from 11.03.2021

3D CoSeedis™ is now also available in the United States.

abc biopply enters into a strategic partnership with Quadira Biosciences, to create a sustainable concept for the development of highly effective therapeutic antibodies without animal testing.

Cooperation of abc biopply with CELLdynamics demonstrates that 3D CoSeedis™ outperforms conventional 3D cell culture systems in generating highly homogenous and uniform spheroids.

Welcome to Chayon Laboratories – our new partner in Korea.

3D CoSeedis™ has been recommended as the tool of choice in the production of extracellular vesicles (EV) from 3D cultures. The chapter in Methods in Enzymology gives a detailed introduction into the isolation of EVs from highly homogenous and uniform 3D cultures using the 3D CoSeedis™ system.

Our international distribution network expands.

Sign up for the next webinar about the latest news about 3D CoSeedis™.

A new white paper is available.

The webinar with our medical advisor Dr. Andreas Thomsen takes place on 14 May 2020.

3D CoSeedis™: the ideal 3D model to grow primary cells.

After many fruitful conversations in the USA we return home with a huge suitcase full of helpful information.

Visit our symposium on Tuesday, 12 November in Berlin.

3D CoSeedis™ goes 24! Have a look at our new format of the 3D cell co-culture system.

Thank you to our partners.

Special thanks to our Medical Advisor and Regina Rufener.

abc biopply goes to the UK:. Thistle Scientific becomes abc biopply’s distribution partner in the UK.

Meet us at ILMAC in Basel

The method can perform fluorescent based viability/cytotoxicity tests on spheroidal and non-spheroidal 3D constructs.

The authors made use of the 3D CoSeedis™ system to assess radiation resistance in 3D conditions via a colony forming assay (CFA).

A new publication on the colony forming assay in cancer research is available.

The sales team of BioConcept, our partner in Switzerland, visited us and attended a training day about 3D CoSeedis™.

The talk about the unique microenvironments in 3D models has been a great success.

Our product family is growing.

The symposium was a complete success.

Visit the symposium in Munich on 27 March 2019.

Visit us on 5 February 2019 in France and learn more about 3D CoSeedis™.

3D CoSeedis™ has recently been used in a study on extracellular vesicle composition.

3D CoSeedis™ is now available in Germany, Austria, France and Canada.

A new publication about 3D CoSeedis™ is available.

abc biopply has developed a standardised way to conveniently embed 3D cell aggregates grown in the 3D CoSeedis™ matrix in paraffin for immunological analysis. In this context we haverecently also started a partnership with AnaPath.

abc biopply is introducing a fully standardised 3D micro-tumour system based on its 3D CoSeedis™ technology platform.

abc biopply launches a new 3D CoSeedis™ system in June.

Visit us at our booth E2 at the DECHEMA 3D Cell Culture Congress in Freiburg (DE)

Learn more about 3D CoSeedis™ and ask the experts directly.

We have received attention in various newspapers.